Heredity, gender and the discourse of ovarian cancer

New Genetics and Society

Volumn 25, Issue 2, 2006, Pages 171-196

  Happe, Kelly E ^a  

^a NORTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; GENETIC PROCEDURES; HEREDITY; HUMAN; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; WOMEN'S HEALTH;

EID: 33748520898     PISSN: 14636778     EISSN: 14699915     Source Type: Journal    
DOI: 10.1080/14636770600855226     Document Type: Review

References (69)

1. Aitken, J.M. et al. (1973) Osteoporosis after oophorectomy for non-malignant disease in premenopausal women, British Medical Journal, 2, pp. 325-8.
2. Aliyu, M.H. et al. (2005) Trends in birth across high-parity groups by race/ethnicity and maternal age, Journal of the National Medical Association, 97(6), pp. 799-804.
3. American Cancer Society (2005) Cancer Statistics 2005 (power point presentation), available at www.cancer.org/docroot/STT/stt_0.asp (accessed January 2006).
4. Armstrong, K. et al. (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis, Journal of Clinical Oncology, 22(6), pp. 1045-54.
5. Bourne, T.H. et al. (1991) Ultrasound screening for familial ovarian cancer, Gynecologic Oncology, 43, pp. 92-7.
6. Boyd, J. (2001) BRCA: the breast, ovarian, and other cancer genes, Gynecologic Oncology, 80, pp. 337-40.
7. Broder, M.S. et al. (2000) The appropriateness of recommendations for hysterectomy, Obstetrics & Gynecology, 95(2), pp. 199-205.
8. Burke, W. et al. (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer, JAMA, 277(12), pp. 997-1003.
9. Cass, I. et al. (2003) Improved survival in women with BRCA-associated ovarian carcinoma, Cancer, 97(9), pp. 2187-95.
10. Centers for Disease Control (2006) Ovarian Cancer: Facing the Challenge (2004/2005 Fact Sheet), available at http://www.cdc.gov/cancer/ovarian/ about2004.htm
11. Colditz, G.A. et al. (1987) Menopause and the risk of coronary heart disease in women, New England Journal of Medicine, 316(18), pp. 1105-10.
12. Colgan, T.J. (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status, The American Journal of Surgical Pathology, 25(10), pp. 1283-9.
13. Dewailly, E. et al. (1994) High organochlorine body burden in women with estrogen receptor-positive breast cancer, Journal of the National Cancer Institute, 86, pp. 232-4.
14. Dewailly, E. et al. (1997) Could the rising levels of estrogen receptor in breast cancer be due to estrogenic pollutants?, Journal of the National Cancer Institute, 89, pp. 888-9.
15. Ehrenreich, B. & English, D. (1978) For Her Own Good: 150 Years of the Experts' Advice to Women (New York: Doubleday).
16. Eisen, A. & Weber, B.L. (1998) Primary peritoneal carcinoma can have multifocal origins: implications for prophylactic oophorectomy, Journal of the National Cancer Institute, 90(11), pp. 797-9.
17. Eisen, A. et al. (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer, Journal of Clinical Oncology, 18(9), pp. 1980-95.
18. Fasouliotis, S. & Schenker, J. (2000) BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management, Obstetrical and Gynecological Survey, 55, pp. 373-84.
19. Fausto-Sterling, A. (1992) Myths of Gender: Biological Theories about Women and Men (New York: Basic Books).
20. Gallion, H.H. & Park, R. (1995) Developing intervention/prevention strategies for individuals at high risk of developing hereditary ovarian cancer, Journal of the National Cancer Institute Monographs, 17, pp. 103-6.
21. Garber, J.E. & Hartman, A.-R. (2004) Prophylactic oophorectomy and hormone replacement therapy: protection at what price?, Journal of Clinical Oncology, 22(6), pp. 978-80.
22. Grann, V.R. et al. (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA 1/2 mutations: an updated decision analysis, Journal of Clinical Oncology, 20(10), pp. 2520-9.
23. Haber, D. (2002) Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations, New England Journal of Medicine, 346(21), pp. 1660-2.
24. Hall, J.M. et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21, Science, 250, pp. 1684-9.
25. Hartmann, L. et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, New England Journal of Medicine, 340(2), pp. 77-84.
26. Healy, B. (1997) BRCA genes-bookmaking, fortunetelling, and medical care. New England Journal of Medicine, 336 (May 15), pp. 1448-9.
27. Heffner, L.J. (2004) Advanced maternal age: how old is too old?, New England Journal of Medicine, 351(19), pp. 1927-9.
28. Holt, J.T. et al. (1996) Growth retardation and tumour inhibition by BRCA1, Nature Genetics, 12, pp. 298-302.
29. Hubbard, R. (1996) Pointless to test for gene linked to breast cancer? Yes, Washington Post, 28 May, Z19, available at http://web.lexis-nexis.com/ universe.
30. Huggins, C. & Dao, T.L.-Y. (1953) Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast, JAMA, 151(16), pp. 1388-94.
31. Hunter, D.J. et al. (1997) Plasma organochlorine levels and the risk of breast cancer, New England Journal of Medicine, 337, pp. 1253-8.
32. Jensen, R.A. et al. (1996) BRCA1 is secreted and exhibits properties of a granin, Nature Genetics, 12, pp. 303-8.
33. Karlan, B.Y. (2004) Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis, Gynecologic Oncology, 92, pp. 519-20.
34. Kauff, N.D. & Barakat, R.R. (2004) Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?, Gynecologic Oncology, 93, p. 277-9.
35. Kauff, N.D. et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, New England Journal of Medicine, 246(21), pp. 1609-15.
36. King, M.-C. et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2, JAMA, 286(18), pp. 2251-6.
37. King, M.-C. et al. (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, pp. 643-6.
38. Krieger, N. (1989) Exposure, susceptibility, and breast cancer risk: a hypothesis regarding exogenous carcinogens, breast tissue development and social gradients, including black/white differences, in breast cancer incidence, Breast Cancer Research and Treatment, 13(3), pp. 205-23.
39. Krieger, N. et al. (1994) Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women, Journal of the National Cancer Institute, 86, pp. 589-99.
40. Lavie, O. et al. (2004) BRCA germline mutations in Jewish women with uterine serious papillary carcinoma, Gynecologic Oncology, 92, pp. 521-4.
41. Lerner, B.H. (2001) The Breast Cancer Wars: Hope, Fear, and the Pursuit of a Cure in Twentieth-Century America (New York: Oxford University Press).
42. Levine, D. et al. (2003) Fallopian tube and primary peritoneal carcinoma associated with BRCA mutations, Journal of Clinical Oncology, 21(22), pp. 4222-7.
43. Liede, A. et al. (2002) Cancer incidence in a population of Jewish women at risk of ovarian cancer, Journal of Clinical Oncology, 20(6), pp. 1570-7.
44. Marquis, S.T. et al. (1995) The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues, Nature Genetics, 11, pp. 17-26.
45. Martin, E. (1987) The Women in the Body: A Cultural Analysis of Reproduction (Boston, MA: Beacon Press).
46. Massachusetts Breast Cancer Coalition (2000) Beyond the Headlines Issue paper 1 (July).
47. Miki, Y. et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, pp. 66-71.
48. Narod, S.A. et al. (1991)Familial breast-ovarian cancer locus on chromosome 17q12-q23, Lancet, 338, pp. 82-3.
49. Olopade, O. & Artioli, G. (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations, The Breast Journal, 10(S1), pp. S5-S9.
50. Patterson, J.T. (1987) The Dread Disease: Cancer and Modern American Culture (Cambridge, MA: Harvard University Press).
51. Piver, M.S. et al. (1993a) Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991, Cancer Supplement, 71(2), pp. 582-8.
52. Piver, M.S. et al. (1993b) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry, Cancer, 71(9), p. 2751-5.
53. Rebbeck, T.R. et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, New England Journal of Medicine, 346(21), pp. 1616-22.
54. Risch, H.A. et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer, American Journal of Human Genetics, 68, pp. 700-10.
55. Roberts, D. (1999) Killing the Black Body: Race, Reproduction, and the Meaning of Liberty (New York: Vintage).
56. Rosen, B. et al. (2004) Systematic review of management options for women with a hereditary predisposition to ovarian cancer, Gynecologic Oncology, 93, pp. 280-6.
57. Rothman, B.K. (1998) Genetic Maps and Human Imaginations: The Limits of Science in Understanding Who We Are (New York: WW Norten).
58. Rubin, S.C. (2003) BRCA-related ovarian carcinoma: another piece of the puzzle?, Cancer, 97(9), pp. 2127-9.
59. Runowicz, C.D. (1999) Appendix VIII: Prophylactic oophorectomy. New York State Department of Health. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. On file with author.
60. Samuels, S. (1996) The fetal protection debate revisited: the impact of U.A.W. v. Johnson Controls on the federal and state courses, Women's Rights Law Reporter, 17, pp. 209-22 (available from Academic Universe database).
61. Schrag, D. et al. (1997) Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations, New England Journal of Medicine, 336(20), pp. 1465-71.
62. Seltzer, V. et al. (1995) Ovarian cancer: screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer, JAMA, 273(6), pp. 491-7.
63. Spear, S. et al. (1999) Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2 positive patient, Plastic and Reconstructive Surgery, 103(2), pp. 548-53.
64. Steingraber, S. (1998) Living Downstream: A Scientist's Personal Investigation of Cancer and the Environment (Reading: Addison-Wesley Publishing).
65. Struewing, J.P. et al. (1995) Prophylactic oophorectomy in inherited breast/ovarian cancer families, Journal of the National Cancer Institute Monographs, 17, pp. 33-5.
66. Tobacman, J.K. et al. (1982) Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families, The Lancet, 2(8302), 9 October, 795-7.
67. van Nagell, J.R., Jr (1991) Editorial, Gynecologic Oncology, 43, pp. 89-91.
68. Wolff, M.S. et al. (1993) Blood levels of organochlorine residues and risk of breast cancer, Journal of the National Cancer Institute, 85, pp. 648-52.
69. Wooster, R. et al. (1995) Identification of the breast cancer susceptibility gene BRCA2, Nature, 378, pp. 789-92.